Evidence map›Paper›PMID 32296997›Full record

ArticleJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry2020

A multi-methodological inquiry of the behavior of cisplatin-based Pt(IV) derivatives in the presence of bioreductants with a focus on the isolated encounter complexes.

Davide Corinti, Maria Elisa Crestoni, Simonetta Fornarini, Eslam Dabbish, Emilia Sicilia, Elisabetta Gabano, Elena Perin, Domenico Osella

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Davide CorintiDipartimento di Chimica e Tecnologie del Farmaco, Università di Roma "La Sapienza", P.le A. Moro 5, 00185, Rome, Italy. davide.corinti@uniroma1.it.ORCID 0000-0001-8064-3492
Maria Elisa CrestoniDipartimento di Chimica e Tecnologie del Farmaco, Università di Roma "La Sapienza", P.le A. Moro 5, 00185, Rome, Italy.ORCID 0000-0002-0991-5034
Simonetta FornariniDipartimento di Chimica e Tecnologie del Farmaco, Università di Roma "La Sapienza", P.le A. Moro 5, 00185, Rome, Italy.ORCID 0000-0002-6312-5738
Eslam DabbishDepartment of Chemistry and Chemical Technologies, Università della Calabria, Ponte P. Bucci Cubo 14c, 87035, Arcavacata di Rende (CS), Italy. eslammoustafa6@gmail.com.
Emilia SiciliaDepartment of Chemistry and Chemical Technologies, Università della Calabria, Ponte P. Bucci Cubo 14c, 87035, Arcavacata di Rende (CS), Italy.
Elisabetta GabanoDipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121, Alessandria, Italy. elisabetta.gabano@uniupo.it.ORCID 0000-0002-1181-1955
Elena PerinDipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121, Alessandria, Italy.ORCID 0000-0002-4493-7124
Domenico OsellaDipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale T. Michel 11, 15121, Alessandria, Italy.ORCID 0000-0002-6706-9454
Sapienza University of Rome · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Calabria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of Pt(IV) antitumor prodrugs able to circumvent some drawbacks of the conventional Pt(II) chemotherapeutics is the focus of a lot of attention. This paper reports a thorough study based on experimental methods (reduction kinetics, electrochemistry, tandem mass spectrometry and IR ion spectroscopy) and quantum-mechanical DFT calculations on the reduction mechanism of cisplatin-based Pt(IV) derivatives having two hydroxido (1), one hydroxido and one acetato (2), or two acetato ligands (3) in axial position. The biological reductants glutathione and ascorbic acid were taken into consideration. The presence of a hydroxido ligand resulted to play an important role in the chemical reduction with ascorbic acid, as verified by

Indexed as

Antineoplastic AgentsCisplatinDensity Functional TheoryMolecular ConformationOrganoplatinum CompoundsOxidation-ReductionStereoisomerismAntineoplastic AgentsCisplatinOrganoplatinum Compounds15N-NMR spectroscopyAntitumor prodrugDFT calculationsIR ion spectroscopyMass spectrometryReduction kinetics

Identifiers

PMID32296997
OpenAlexW3016422819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.